Your signal. Your price.
The FDA approved synthetic Exendin-4 (Byetta/Exenatide) in 2005 as the first GLP-1 receptor agonist for type 2 diabetes, paving the way for drugs like semaglutide and tirzepatide.
Only 1 result for these filters — try broadening your search